These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 27292320)

  • 1. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
    Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
    Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival.
    Kamai T; Kijima T; Tsuzuki T; Nukui A; Abe H; Arai K; Yoshida KI
    Cancer Immunol Immunother; 2021 Jul; 70(7):2009-2021. PubMed ID: 33416945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma.
    Mikami S; Mizuno R; Kondo T; Shinohara N; Nonomura N; Ozono S; Eto M; Tatsugami K; Takayama T; Matsuyama H; Kishida T; Oya M;
    Cancer Sci; 2019 Jun; 110(6):1820-1828. PubMed ID: 30972888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
    Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
    Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.
    Choueiri TK; Lim ZD; Hirsch MS; Tamboli P; Jonasch E; McDermott DF; Dal Cin P; Corn P; Vaishampayan U; Heng DY; Tannir NM
    Cancer; 2010 Nov; 116(22):5219-25. PubMed ID: 20665500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments.
    Fumarola C; La Monica S; Bonelli M; Zoppi S; Alfieri R; Galetti M; Gnetti L; Campanini N; Pozzi G; Cavazzoni A; Mazzaschi G; Silini EM; Buti S; Petronini PG
    Biochem Pharmacol; 2024 Aug; 226():116397. PubMed ID: 38944394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies.
    Pulanco MC; Madsen AT; Tanwar A; Corrigan DT; Zang X
    Cell Mol Immunol; 2023 Jul; 20(7):694-713. PubMed ID: 37069229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma.
    Jikuya R; Kishida T; Sakaguchi M; Yokose T; Yasui M; Hashizume A; Tatenuma T; Mizuno N; Muraoka K; Umemoto S; Kawai M; Yoshihara M; Nakamura Y; Miyagi Y; Sasada T
    Cancer Immunol Immunother; 2020 Oct; 69(10):2041-2051. PubMed ID: 32424467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression.
    Lu Y; Wu F; Cao Q; Sun Y; Huang M; Xiao J; Zhou B; Zhang L
    Oncogene; 2022 Jan; 41(5):704-717. PubMed ID: 34839353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to post-axitinib treatment in patients with metastatic renal cell carcinoma.
    Chittoria N; Haddad H; Elson P; Tannir NM; Wood LS; Dreicer R; Garcia JA; Rini BI; Jonasch E
    BMC Cancer; 2016 Mar; 16():254. PubMed ID: 27026229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of blocking novel immune checkpoint B7-H4 in urothelial carcinoma of bladder as a potential therapeutic target.
    Raja D; Singh A; Kurra S; Nayak B; Kaushal S; Sharma A; Singh P
    Med Oncol; 2024 Feb; 41(3):74. PubMed ID: 38376603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
    Naffrichoux J; Poupin P; Pouillot W; Linassier C; Rioux-Leclercq N; De Vries-Brilland M; Mourey L; Laguerre B; Oudard S; Gross-Goupil M; Mousset C; Gravis G; Rolland F; Moise L; Emambux S; Vassal C; Zanetta S; Penel N; Albiges L; Fromont G; Cancel M
    Eur J Cancer; 2024 Jul; 205():114121. PubMed ID: 38749111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High serum PD-L1 level is a poor prognostic biomarker in surgically treated esophageal cancer.
    Ito M; Yajima S; Suzuki T; Oshima Y; Nanami T; Sumazaki M; Shiratori F; Funahashi K; Tochigi N; Shimada H
    Cancer Med; 2020 Feb; 9(4):1321-1327. PubMed ID: 31865635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies.
    Ding L; Dong HY; Zhou TR; Wang YH; Yan T; Li JC; Wang ZY; Li J; Liang C
    Cancer Med; 2021 Sep; 10(18):6384-6401. PubMed ID: 34382349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective.
    Lavacchi D; Pellegrini E; Palmieri VE; Doni L; Mela MM; Di Maida F; Amedei A; Pillozzi S; Carini M; Antonuzzo L
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32630154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma.
    Mizuno T; Kamai T; Tsuzuki T; Nishihara D; Kijima T; Arai K; Yoshida KI
    Cancer Immunol Immunother; 2022 Mar; 71(3):565-578. PubMed ID: 34275008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.
    Baine MK; Turcu G; Zito CR; Adeniran AJ; Camp RL; Chen L; Kluger HM; Jilaveanu LB
    Oncotarget; 2015 Sep; 6(28):24990-5002. PubMed ID: 26317902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma.
    Chandrasekaran D; Sundaram S; N K; R P
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):2951-2957. PubMed ID: 31653140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor.
    Gebrael G; Jo Y; Mathew Thomas V; Li H; Sayegh N; Tripathi N; Srivastava A; Nordblad B; Dal E; Narang A; Brundage J; Campbell P; Galarza Fortuna G; Hage Chehade C; Maughan BL; Agarwal N; Swami U
    Cancer; 2024 Aug; 130(15):2621-2628. PubMed ID: 38564301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-H4 expression indicates poor prognosis of oral squamous cell carcinoma.
    Wu L; Deng WW; Yu GT; Mao L; Bu LL; Ma SR; Liu B; Zhang WF; Sun ZJ
    Cancer Immunol Immunother; 2016 Sep; 65(9):1035-45. PubMed ID: 27383830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.